Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Oncolytics Biotech Inc (ONCY)
Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will host a key opinion leader webinar to discuss data from the randomized...

ONC.TO : 2.68 (+13.56%)
ONCY : 1.7500 (-18.98%)
Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will host a key opinion leader webinar to discuss data from the randomized phase...

ONCY : 1.7500 (-18.98%)
ONC.TO : 2.68 (+13.56%)
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

/PRNewswire/ -- USA News Group - The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with...

ONC.TO : 2.68 (+13.56%)
GILD : 77.09 (-0.72%)
IMGN : 14.00 (+1.30%)
DAWN : 12.47 (+3.40%)
LEGN : 63.13 (-0.24%)
ONCY : 1.7500 (-18.98%)
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END

ONCY : 1.7500 (-18.98%)
ONC.TO : 2.68 (+13.56%)
GILD : 77.09 (-0.72%)
IMGN : 14.00 (+1.30%)
DAWN : 12.47 (+3.40%)
LEGN : 63.13 (-0.24%)
Promising New Cancer Treatment Data to Be Presented at 2023 ASCO Annual Meeting

VANCOUVER - USA News Group - The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already...

ONCY : 1.7500 (-18.98%)
ONC.TO : 2.68 (+13.56%)
GILD : 77.09 (-0.72%)
IMGN : 14.00 (+1.30%)
DAWN : 12.47 (+3.40%)
LEGN : 63.13 (-0.24%)
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END

ONCY : 1.7500 (-18.98%)
ONC.TO : 2.68 (+13.56%)
PFE : 37.60 (-0.61%)
OCEA : 5.17 (-0.19%)
NVS : 97.86 (+0.08%)
RLAY : 11.00 (-1.96%)
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028

/PRNewswire/ -- Metastatic breast cancer is the advanced stage of breast cancer, including cases wherein cancer has spread to the other parts of the body from...

ONC.TO : 2.68 (+13.56%)
ONCY : 1.7500 (-18.98%)
PFE : 37.60 (-0.61%)
OCEA : 5.17 (-0.19%)
NVS : 97.86 (+0.08%)
RLAY : 11.00 (-1.96%)
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off date...

ONCY : 1.7500 (-18.98%)
ONC.TO : 2.68 (+13.56%)
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2-...

ONCY : 1.7500 (-18.98%)
ONC.TO : 2.68 (+13.56%)
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2-...

ONCY : 1.7500 (-18.98%)

Barchart Exclusives

Could Aggressive Options Traders Win Out with Rivian Automotive (RIVN)?
Although Rivian Automotive’s new drive unit announcement offers encouragement, options traders also need to consider broader challenges stymieing RIVN stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar